Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372940 | 1.00 | APP (0.57) | APPEGFRPOLBNR2F2NPC1 | |
| SCHEMBL29370429 | 0.85 | KDM4E (0.57) | APPEGFRPOLBNPC1RAB9A | |
| SCHEMBL3765296 | 0.83 | TP53 (0.48) | APPEGFRPOLBNR2F2NPC1 | |
| SCHEMBL3753939 | 0.83 | TP53 (0.48) | APPEGFRPOLBNR2F2TP53 | |
| SCHEMBL3753974 | 0.83 | APP (0.60) | APPNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL3121603 | 0.82 | MAP2K4 (0.58) | APPEGFRPOLBNR2F2TP53 | |
| SCHEMBL3108720 | 0.82 | MAP2K4 (0.61) | APPEGFRPOLBNR2F2TP53 | |
| SCHEMBL3918436 | 0.81 | POLB (0.58) | EGFRPOLBNPC1RAB9ATP53 | |
| SCHEMBL509566 | 0.81 | EGFR (0.64) | APPEGFRPOLBNR2F2NPC1 | |
| SCHEMBL3765283 | 0.80 | POLB (0.50) | APPEGFRPOLBNR2F2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-7842805-B2 | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| EP-1833803-A4 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1833803-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074223-A2 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020985-A1 | PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CASP3, CASP2, CASP5 | APP 732/4885EGFR 3245/4885POLB 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.